TAIM
BIIB icon

TD Ameritrade Investment Management’s Biogen BIIB Stock Holding History

TD Ameritrade Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-177
Closed -$37K – 609
2022
Q1 		$37K Sell
177
-3
-2% -$652 ﹤0.01% 382
2021
Q4 		$43K Buy
+180
New +$46.3K ﹤0.01% 361
2020
Q1 		– Sell
-136
Closed -$40K – 616
2019
Q4 		$40K Buy
136
+6
+5% +$1.67K ﹤0.01% 331
2019
Q3 		$30K Hold
130
– – ﹤0.01% 344
2019
Q2 		$30K Buy
+130
New +$30K ﹤0.01% 299
2019
Q1 		– Sell
-11
Closed -$3K – 572
2018
Q4 		$3K Buy
11
+7
+175% +$2.23K ﹤0.01% 493
2018
Q3 		$1K Buy
+4
New +$1.38K ﹤0.01% 523

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TD Ameritrade Investment Management's BIIB Position: Q2 2022 in Review

TD Ameritrade Investment Management sold out of Biogen (BIIB) in Q2 2022, closing a stake of 177 shares — an estimated $37K sold.

TD Ameritrade Investment Management first reported a position in BIIB in Q3 2018 and held it in 7 quarters. The position peaked at $43K in Q4 2021. 927 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

  • TD Ameritrade Investment Management reported no remaining Biogen position as of Q2 2022 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 177 Biogen shares in Q2 2022, an estimated $37K.
  • TD Ameritrade Investment Management first reported a position in Biogen in Q3 2018 and held it in 7 quarters.
  • TD Ameritrade Investment Management's Biogen position peaked at $43K in Q4 2021.
  • 927 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on TD Ameritrade Investment Management's 13F filing for Q2 2022, filed 9 Aug 2022.